A-116 Evaluation of Lp(a) Ultra assay for the Immunoturbidimetric Quantitative Determination of Lipoprotein (a) in Human Serum and Plasma With Siemens Healthineers Atellica CH 930 Analyzer

Abstract Objective The aim of this study is to evaluate the analytical performances of the Lp(a) Ultra assay for the immunoturbidimetric quantitative determination of lipoprotein (a) in human serum and plasma on Siemens Healthineers Atellica CH 930 Analyzer. Background Lipoprotein (a) has been found...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical chemistry (Baltimore, Md.) Md.), 2023-09, Vol.69 (Supplement_1)
Hauptverfasser: Cugini, A, De Angelis, L, Lucini, R, Brambilla, S
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Supplement_1
container_start_page
container_title Clinical chemistry (Baltimore, Md.)
container_volume 69
creator Cugini, A
De Angelis, L
Lucini, R
Brambilla, S
description Abstract Objective The aim of this study is to evaluate the analytical performances of the Lp(a) Ultra assay for the immunoturbidimetric quantitative determination of lipoprotein (a) in human serum and plasma on Siemens Healthineers Atellica CH 930 Analyzer. Background Lipoprotein (a) has been found in artery walls and can have atherogenic effects. Because of its structural similarity to plasminogen, it can also inhibit fibrinolysis and hence acts thrombogenically. High Lp(a) concentrations in serum correlate with premature manifestation of atherosclerosis and strokes. In combination with elevated LDL Cholesterol concentrations, the coronary risk increases approximately six-fold. Methods Lp(a) Ultra is a latex immunoassay manufactured by Sentinel Diagnostics and developed to measure Lp(a) levels. If the antigen-antibody reaction takes place between Lp(a) in the sample and the anti-Lp(a) antibodies, which have been adsorbed to latex particles, agglutination occurs. This agglutination is detected as an absorbance change, with the magnitude of the change being proportional to the quantity of Lp(a) contained in the sample. Results The Limit of Blank LOB (4 samples × 5 replicates × 3 runs) was ≤2.0 mg/dL. The Limit of Detection LOD (4 samples × 5 replicates × 3 runs) was ≤ 3.0 mg/dL. The Limit of Quantitation LOQ (8 dilution levels × 10 replicates × 3 runs) was ≤5.0 mg/dL at %CV lower than 20%. The Intra Assay (5 samples × 20 replicates × 3 runs) gave the following %CVs: 2.4% at 12.1 mg/dL, 0.8% at 30.3 mg/dL, 0.6% at 47.8 mg/dL, 0.5% at 58.8 mg/dL, 1.7% at 87.1 mg/dL. Total precision study (5 samples × 2 runs × 2 replicates × 20 runs) gave the following %CVs: 4.0% at 11.5 mg/dL, 3.6% at 21.7 mg/dL, 3.0% at 32.0 mg/dL, 2.8% at 42.2 mg/dL, 2.3% at 50.7 mg/dL. The test was linear up to 130 mg/dL. Calibration stability was up to 30 days. Reagent on board stability was up to 30 days. This application (y) was compared with the same test applied on Beckman Coulter AU680 Analyzer (x) and gave the following results: using Passing Bablok analysis: y = 0.8 + 1.0x; correlation coefficient (r) = 0.997; using Deming analysis: y = 1.0 + 1.0x; correlation coefficient (r) = 0.997; number of samples = 120. There is not Hook effect/antigen excess up to 600 mg/dL. Conclusions Analytical performances of Lp(a) Ultra assay on Siemens Healthineers Atellica CH 930 Analyzer meet the requirements for its use as immunoturbidimetric quantitative determination of lipoprotein (a) in human s
doi_str_mv 10.1093/clinchem/hvad097.106
format Article
fullrecord <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_clinchem_hvad097_106</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/clinchem/hvad097.106</oup_id><sourcerecordid>10.1093/clinchem/hvad097.106</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1316-4ae0d4d11996cc38117819189d646490a93b55097491e756b4f7661543702a03</originalsourceid><addsrcrecordid>eNqNkcGK1EAQhhtRcFx9Aw911EOcLtPppI_DuOssDKjsisdQk1RIS3cndHcGxmfz4cyyK149_dQP33-oT4i3KD-gNOW2czZ0I_vteKZemnpt9TOxwaqURVNpfC42UkpTGFT1S_EqpZ_rqepGb8TvXYGo4fpMbqFspwDTAMf5Hb2H7y5HAkqJLjBMEfLIcOv9Eqa8xJPtreccbQffFgrZ5pU-M3zizNHb8G_LztMcp8w2wMPqGofFU4A7josHCj18dZQ8wQ-bR7iz7DkkODC5PNrAHBPsMjtnO4L9AUwpYRfIXX5xfC1eDOQSv3nKK3F_c32_PxTHL59v97tj0WGJulDEslc9ojG668oGsW7QYGN6rbQykkx5qqr1b8og15U-qaHWGitV1vIjyfJKqMfZLk4pRR7aOVpP8dKibB8EtH8FtE8C1lav2PYRm5b5_4g_gcGNQg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A-116 Evaluation of Lp(a) Ultra assay for the Immunoturbidimetric Quantitative Determination of Lipoprotein (a) in Human Serum and Plasma With Siemens Healthineers Atellica CH 930 Analyzer</title><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Cugini, A ; De Angelis, L ; Lucini, R ; Brambilla, S</creator><creatorcontrib>Cugini, A ; De Angelis, L ; Lucini, R ; Brambilla, S</creatorcontrib><description>Abstract Objective The aim of this study is to evaluate the analytical performances of the Lp(a) Ultra assay for the immunoturbidimetric quantitative determination of lipoprotein (a) in human serum and plasma on Siemens Healthineers Atellica CH 930 Analyzer. Background Lipoprotein (a) has been found in artery walls and can have atherogenic effects. Because of its structural similarity to plasminogen, it can also inhibit fibrinolysis and hence acts thrombogenically. High Lp(a) concentrations in serum correlate with premature manifestation of atherosclerosis and strokes. In combination with elevated LDL Cholesterol concentrations, the coronary risk increases approximately six-fold. Methods Lp(a) Ultra is a latex immunoassay manufactured by Sentinel Diagnostics and developed to measure Lp(a) levels. If the antigen-antibody reaction takes place between Lp(a) in the sample and the anti-Lp(a) antibodies, which have been adsorbed to latex particles, agglutination occurs. This agglutination is detected as an absorbance change, with the magnitude of the change being proportional to the quantity of Lp(a) contained in the sample. Results The Limit of Blank LOB (4 samples × 5 replicates × 3 runs) was ≤2.0 mg/dL. The Limit of Detection LOD (4 samples × 5 replicates × 3 runs) was ≤ 3.0 mg/dL. The Limit of Quantitation LOQ (8 dilution levels × 10 replicates × 3 runs) was ≤5.0 mg/dL at %CV lower than 20%. The Intra Assay (5 samples × 20 replicates × 3 runs) gave the following %CVs: 2.4% at 12.1 mg/dL, 0.8% at 30.3 mg/dL, 0.6% at 47.8 mg/dL, 0.5% at 58.8 mg/dL, 1.7% at 87.1 mg/dL. Total precision study (5 samples × 2 runs × 2 replicates × 20 runs) gave the following %CVs: 4.0% at 11.5 mg/dL, 3.6% at 21.7 mg/dL, 3.0% at 32.0 mg/dL, 2.8% at 42.2 mg/dL, 2.3% at 50.7 mg/dL. The test was linear up to 130 mg/dL. Calibration stability was up to 30 days. Reagent on board stability was up to 30 days. This application (y) was compared with the same test applied on Beckman Coulter AU680 Analyzer (x) and gave the following results: using Passing Bablok analysis: y = 0.8 + 1.0x; correlation coefficient (r) = 0.997; using Deming analysis: y = 1.0 + 1.0x; correlation coefficient (r) = 0.997; number of samples = 120. There is not Hook effect/antigen excess up to 600 mg/dL. Conclusions Analytical performances of Lp(a) Ultra assay on Siemens Healthineers Atellica CH 930 Analyzer meet the requirements for its use as immunoturbidimetric quantitative determination of lipoprotein (a) in human serum and plasma and make this assay very suitable for the routine measurement of this analyte.</description><identifier>ISSN: 0009-9147</identifier><identifier>EISSN: 1530-8561</identifier><identifier>DOI: 10.1093/clinchem/hvad097.106</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><ispartof>Clinical chemistry (Baltimore, Md.), 2023-09, Vol.69 (Supplement_1)</ispartof><rights>Association for Diagnostics and Laboratory Medicine 2023. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Cugini, A</creatorcontrib><creatorcontrib>De Angelis, L</creatorcontrib><creatorcontrib>Lucini, R</creatorcontrib><creatorcontrib>Brambilla, S</creatorcontrib><title>A-116 Evaluation of Lp(a) Ultra assay for the Immunoturbidimetric Quantitative Determination of Lipoprotein (a) in Human Serum and Plasma With Siemens Healthineers Atellica CH 930 Analyzer</title><title>Clinical chemistry (Baltimore, Md.)</title><description>Abstract Objective The aim of this study is to evaluate the analytical performances of the Lp(a) Ultra assay for the immunoturbidimetric quantitative determination of lipoprotein (a) in human serum and plasma on Siemens Healthineers Atellica CH 930 Analyzer. Background Lipoprotein (a) has been found in artery walls and can have atherogenic effects. Because of its structural similarity to plasminogen, it can also inhibit fibrinolysis and hence acts thrombogenically. High Lp(a) concentrations in serum correlate with premature manifestation of atherosclerosis and strokes. In combination with elevated LDL Cholesterol concentrations, the coronary risk increases approximately six-fold. Methods Lp(a) Ultra is a latex immunoassay manufactured by Sentinel Diagnostics and developed to measure Lp(a) levels. If the antigen-antibody reaction takes place between Lp(a) in the sample and the anti-Lp(a) antibodies, which have been adsorbed to latex particles, agglutination occurs. This agglutination is detected as an absorbance change, with the magnitude of the change being proportional to the quantity of Lp(a) contained in the sample. Results The Limit of Blank LOB (4 samples × 5 replicates × 3 runs) was ≤2.0 mg/dL. The Limit of Detection LOD (4 samples × 5 replicates × 3 runs) was ≤ 3.0 mg/dL. The Limit of Quantitation LOQ (8 dilution levels × 10 replicates × 3 runs) was ≤5.0 mg/dL at %CV lower than 20%. The Intra Assay (5 samples × 20 replicates × 3 runs) gave the following %CVs: 2.4% at 12.1 mg/dL, 0.8% at 30.3 mg/dL, 0.6% at 47.8 mg/dL, 0.5% at 58.8 mg/dL, 1.7% at 87.1 mg/dL. Total precision study (5 samples × 2 runs × 2 replicates × 20 runs) gave the following %CVs: 4.0% at 11.5 mg/dL, 3.6% at 21.7 mg/dL, 3.0% at 32.0 mg/dL, 2.8% at 42.2 mg/dL, 2.3% at 50.7 mg/dL. The test was linear up to 130 mg/dL. Calibration stability was up to 30 days. Reagent on board stability was up to 30 days. This application (y) was compared with the same test applied on Beckman Coulter AU680 Analyzer (x) and gave the following results: using Passing Bablok analysis: y = 0.8 + 1.0x; correlation coefficient (r) = 0.997; using Deming analysis: y = 1.0 + 1.0x; correlation coefficient (r) = 0.997; number of samples = 120. There is not Hook effect/antigen excess up to 600 mg/dL. Conclusions Analytical performances of Lp(a) Ultra assay on Siemens Healthineers Atellica CH 930 Analyzer meet the requirements for its use as immunoturbidimetric quantitative determination of lipoprotein (a) in human serum and plasma and make this assay very suitable for the routine measurement of this analyte.</description><issn>0009-9147</issn><issn>1530-8561</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqNkcGK1EAQhhtRcFx9Aw911EOcLtPppI_DuOssDKjsisdQk1RIS3cndHcGxmfz4cyyK149_dQP33-oT4i3KD-gNOW2czZ0I_vteKZemnpt9TOxwaqURVNpfC42UkpTGFT1S_EqpZ_rqepGb8TvXYGo4fpMbqFspwDTAMf5Hb2H7y5HAkqJLjBMEfLIcOv9Eqa8xJPtreccbQffFgrZ5pU-M3zizNHb8G_LztMcp8w2wMPqGofFU4A7josHCj18dZQ8wQ-bR7iz7DkkODC5PNrAHBPsMjtnO4L9AUwpYRfIXX5xfC1eDOQSv3nKK3F_c32_PxTHL59v97tj0WGJulDEslc9ojG668oGsW7QYGN6rbQykkx5qqr1b8og15U-qaHWGitV1vIjyfJKqMfZLk4pRR7aOVpP8dKibB8EtH8FtE8C1lav2PYRm5b5_4g_gcGNQg</recordid><startdate>20230927</startdate><enddate>20230927</enddate><creator>Cugini, A</creator><creator>De Angelis, L</creator><creator>Lucini, R</creator><creator>Brambilla, S</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20230927</creationdate><title>A-116 Evaluation of Lp(a) Ultra assay for the Immunoturbidimetric Quantitative Determination of Lipoprotein (a) in Human Serum and Plasma With Siemens Healthineers Atellica CH 930 Analyzer</title><author>Cugini, A ; De Angelis, L ; Lucini, R ; Brambilla, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1316-4ae0d4d11996cc38117819189d646490a93b55097491e756b4f7661543702a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cugini, A</creatorcontrib><creatorcontrib>De Angelis, L</creatorcontrib><creatorcontrib>Lucini, R</creatorcontrib><creatorcontrib>Brambilla, S</creatorcontrib><collection>CrossRef</collection><jtitle>Clinical chemistry (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cugini, A</au><au>De Angelis, L</au><au>Lucini, R</au><au>Brambilla, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A-116 Evaluation of Lp(a) Ultra assay for the Immunoturbidimetric Quantitative Determination of Lipoprotein (a) in Human Serum and Plasma With Siemens Healthineers Atellica CH 930 Analyzer</atitle><jtitle>Clinical chemistry (Baltimore, Md.)</jtitle><date>2023-09-27</date><risdate>2023</risdate><volume>69</volume><issue>Supplement_1</issue><issn>0009-9147</issn><eissn>1530-8561</eissn><abstract>Abstract Objective The aim of this study is to evaluate the analytical performances of the Lp(a) Ultra assay for the immunoturbidimetric quantitative determination of lipoprotein (a) in human serum and plasma on Siemens Healthineers Atellica CH 930 Analyzer. Background Lipoprotein (a) has been found in artery walls and can have atherogenic effects. Because of its structural similarity to plasminogen, it can also inhibit fibrinolysis and hence acts thrombogenically. High Lp(a) concentrations in serum correlate with premature manifestation of atherosclerosis and strokes. In combination with elevated LDL Cholesterol concentrations, the coronary risk increases approximately six-fold. Methods Lp(a) Ultra is a latex immunoassay manufactured by Sentinel Diagnostics and developed to measure Lp(a) levels. If the antigen-antibody reaction takes place between Lp(a) in the sample and the anti-Lp(a) antibodies, which have been adsorbed to latex particles, agglutination occurs. This agglutination is detected as an absorbance change, with the magnitude of the change being proportional to the quantity of Lp(a) contained in the sample. Results The Limit of Blank LOB (4 samples × 5 replicates × 3 runs) was ≤2.0 mg/dL. The Limit of Detection LOD (4 samples × 5 replicates × 3 runs) was ≤ 3.0 mg/dL. The Limit of Quantitation LOQ (8 dilution levels × 10 replicates × 3 runs) was ≤5.0 mg/dL at %CV lower than 20%. The Intra Assay (5 samples × 20 replicates × 3 runs) gave the following %CVs: 2.4% at 12.1 mg/dL, 0.8% at 30.3 mg/dL, 0.6% at 47.8 mg/dL, 0.5% at 58.8 mg/dL, 1.7% at 87.1 mg/dL. Total precision study (5 samples × 2 runs × 2 replicates × 20 runs) gave the following %CVs: 4.0% at 11.5 mg/dL, 3.6% at 21.7 mg/dL, 3.0% at 32.0 mg/dL, 2.8% at 42.2 mg/dL, 2.3% at 50.7 mg/dL. The test was linear up to 130 mg/dL. Calibration stability was up to 30 days. Reagent on board stability was up to 30 days. This application (y) was compared with the same test applied on Beckman Coulter AU680 Analyzer (x) and gave the following results: using Passing Bablok analysis: y = 0.8 + 1.0x; correlation coefficient (r) = 0.997; using Deming analysis: y = 1.0 + 1.0x; correlation coefficient (r) = 0.997; number of samples = 120. There is not Hook effect/antigen excess up to 600 mg/dL. Conclusions Analytical performances of Lp(a) Ultra assay on Siemens Healthineers Atellica CH 930 Analyzer meet the requirements for its use as immunoturbidimetric quantitative determination of lipoprotein (a) in human serum and plasma and make this assay very suitable for the routine measurement of this analyte.</abstract><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/clinchem/hvad097.106</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0009-9147
ispartof Clinical chemistry (Baltimore, Md.), 2023-09, Vol.69 (Supplement_1)
issn 0009-9147
1530-8561
language eng
recordid cdi_crossref_primary_10_1093_clinchem_hvad097_106
source Oxford University Press Journals All Titles (1996-Current)
title A-116 Evaluation of Lp(a) Ultra assay for the Immunoturbidimetric Quantitative Determination of Lipoprotein (a) in Human Serum and Plasma With Siemens Healthineers Atellica CH 930 Analyzer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T21%3A49%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A-116%20Evaluation%20of%20Lp(a)%20Ultra%20assay%20for%20the%20Immunoturbidimetric%20Quantitative%20Determination%20of%20Lipoprotein%20(a)%20in%20Human%20Serum%20and%20Plasma%20With%20Siemens%20Healthineers%20Atellica%20CH%20930%20Analyzer&rft.jtitle=Clinical%20chemistry%20(Baltimore,%20Md.)&rft.au=Cugini,%20A&rft.date=2023-09-27&rft.volume=69&rft.issue=Supplement_1&rft.issn=0009-9147&rft.eissn=1530-8561&rft_id=info:doi/10.1093/clinchem/hvad097.106&rft_dat=%3Coup_cross%3E10.1093/clinchem/hvad097.106%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/clinchem/hvad097.106&rfr_iscdi=true